AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06672666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partcipants will be given placebo substance to be taken with titrated instructions that mimic IP dispensing method daily for 4 weeks
Trial: NCT06679153
Drug: VVN461 Ophthalmic Solution 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VVN461 Ophthalmic Solution, 1.0%, for up to 28 days
Trial: NCT06679153
Drug: VVN461 Ophthalmic Solution 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VVN461 Ophthalmic Solution, 0.5%, for up to 28 days
Trial: NCT06679153
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone acetate, 1%, for up to 28 days
Trial: NCT06187506
Drug: Bacillus Calmette Guerin Vaccine
RxNorm normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy, i.e., intravesical therapy once a week for 6 weeks. maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
Trial: NCT05619926
Drug: STSP-0601 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Injection
Trial: NCT04349930
Drug: Placebo vaginal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal suppository
Trial: NCT05476796
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/Tipiracil will be administered with a 14-day schedule (35 mg/m² BID for 5 days followed by 9 days of recovery) until disease progression or intolerable toxicity.
Trial: NCT05476796
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.
Trial: NCT05564858
Drug: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib
RxNorm normalized name: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA022-BB05, intravenously infusion, q3w
Trial: NCT04837885
Drug: LUTATHERA® by intra-arterial hepatic (IAH) injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One treatment dose of LUTATHERA® by IAH injection for the 10 first patients with an PET/CT ratio greater then 3.~The LUTATHERA® by intra-arterial hepatic injection treatment is realised after the conventional treatment by 4 intravenous administrations
Trial: NCT05749588
Drug: A1: SHR-A1811
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A1: an anti-HER2 antibody-drug conjugate (ADC)
Trial: NCT05749588
Drug: C2: SHR-A1811 with BP102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)
Trial: NCT05749588
Drug: D1: TROP2 ADC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
Trial: NCT05749588
Drug: E1: SHR-A1811
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E1: an anti-HER2 antibody-drug conjugate (ADC)
Trial: NCT05749588
Drug: F1: TROP2 ADC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
Trial: NCT04207710
Drug: Gebauer's Pain Ease Top Aerosol Mist Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical refrigerant spray
Trial: NCT06239311
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution for injection in prefilled pen
Trial: NCT06239311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection in prefilled pen
Trial: NCT04718064
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once daily, for three consecutive days,
Trial: NCT04670653
Drug: MAGNÓLIA NASAL GEL
RxNorm normalized name: Magnolia champaca flower oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnólia nasal gel spray
Trial: NCT05850377
Drug: 5-Aminolevulinic Acid (5-ALA) Gliolan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials and is administered orally three hours (range 2-4 hours) before anaesthesia. One bottle contains 1.17 g of 5-aminolevulinic acid (5-ALA), corresponding to 1.5 g 5-aminolevulinic acid hydrochloride (5-ALA HCl). The recommended dose is 20 mg 5-ALA HCl per kilogram body weight. One ml of reconstituted solution contains 23.4 mg of 5-ALA, corresponding to 30 mg 5-ALA HCl.
Trial: NCT05008887
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fractional CO2 laser-assisted cutaneous delivery of methotrexate solution in stable, non-segmental vitiligo
Trial: NCT04788563
Drug: Original antihypertensive treatment (preference selection arm)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, patients will maintain their original antihypertensive treatment.
Trial: NCT04933630
Drug: FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
RxNorm normalized name: Selective serotonin reuptake inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants exiting the TRAIT study will have received a 90-day supply of their current protocol-approved antidepressant treatment (ADT) if clinically appropriate, prior to entering the TRAIT-RS study, in addition to a continuity of care letter to be given to their medical provider to facilitate a refill of that medication as desired. (See NCT04748276 for specific formulary and prescribing guidelines).
Trial: NCT04884243
Drug: CBT-006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution
Trial: NCT05032508
Drug: Lidocaïne Aguettant 20 mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaïne Aguettant 20 mg/ml, injectable solution, applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
Trial: NCT05032508
Drug: NaCl 0,9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (NaCl 0,9%), applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
Trial: NCT06184698
Drug: LV
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 2400 mg/m²
Trial: NCT04015557
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
Trial: NCT04676243
Drug: Treatment according to Physician's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usually daunorubicin/ cytarabine or idarubicin/Cytarabine plus FLT3 inhibitor (usually midostaurin)
Trial: NCT04676243
Drug: Standard of Care Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin/ Cytarabine or Idarubicin/Cytarabine
Trial: NCT06394063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Telitacicept
Trial: NCT06256419
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients with T2DM were required to have received GLP-1RA as monotherapy or in combination with other antidiabetic agents. GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM.
Trial: NCT05463133
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Post transplant drug - cyclophosphamide give to prevent graft versus host disease. This is a well studied drug and s not under an IND.
Trial: NCT05463133
Drug: Total Body Irradiation
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplant Conditioning - Total Body Irradiation (300 cGy in fractionated doses) to create space n the subject's bone marrow so that the donor peripheral blood stem cells can repopulate in the subject's bone marrow.
Trial: NCT05597735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control intervention is a placebo and its route of administration will be identical to the experimental intervention administration to allow treatment arm blinding.
Trial: NCT06127212
Drug: Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of the reference drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
Trial: NCT04943211
Drug: fluorodeoxyglucose (18F-FDG)
RxNorm normalized name: fluorodeoxyglucose F18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: max 6 MGBq/kg, no more than 100
Trial: NCT05332444
Drug: susceptibility-guided tailored therapy (Group A)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
Trial: NCT05332444
Drug: guidelines-recommended empiric therapy (Group B)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
Trial: NCT05755789
Drug: Continuous infusion of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of placebo from the end of the loading bolus until the end of surgical closure
Trial: NCT05755789
Drug: Intermittent placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional bolus of placebo every 2 hours until the end of surgical closure
Trial: NCT05690321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of placebo (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
Trial: NCT05282940
Drug: Microgynon CD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microgynon CD will be used as a comparator drug for the BE study. Other Name: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Drug
Trial: NCT05219812
Drug: BAY2395840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, intake orally.
Trial: NCT05219812
Drug: Placebo for BAY2395840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, intake orally.
Trial: NCT06205134
Drug: A: Epinephrine injection
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Autoinjector for intramuscular, single-use, 0.3mg
Trial: NCT06205134
Drug: B: FMXIN002 3.6mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril
Trial: NCT06342921
Drug: 15 mg ADC189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use only once during the whole study.
Trial: NCT06342921
Drug: 45 mg ADC189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use only once during the whole study.
Trial: NCT06342921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use only once during the whole study.
Trial: NCT06170333
Drug: 8% sulphur and A. vera soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in experimental arms will receive the combination of 8% sulphur and A. vera soap for four weeks along with 2% ketoconazole shampoo for a week.
Trial: NCT05215574
Drug: NGM831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
Trial: NCT00002365
Drug: LXR015-1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05203965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two matching tablets of placebo will be administered on the morning of one of the two experimental days by an RN or the physician investigator.
Trial: NCT04946318
Drug: CSJ117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) capsules for inhalation once daily delivered via Concept1 inhalation device for 12 or 24 weeks.
Trial: NCT04946318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaled once daily for 12 or 24 weeks. Delivered via Concept1 device.
Trial: NCT04746040
Drug: Test
RxNorm normalized name: Testro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations of Test and Reference product in each study period
Trial: NCT04746040
Drug: Reference
RxNorm normalized name: Loreal Preference Dark Auburn 4R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations of Test and Reference product in each study period
Trial: NCT05437094
Drug: CRD-740
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRD-740
Trial: NCT04590612
Drug: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet
RxNorm normalized name: carbidopa-levodopa 25 mg-100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg-100mg tablets to be taken orally three times a day on an empty stomach
Trial: NCT05292677
Drug: Steroid/Anesthesia Mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid will be Triamcinolone Acetonide (40mg/mL). Anesthetic will be 0.5% bupivacaine with 1:100,000 epinephrine. These will be pre-mixed by a qualified personnel within the ENT department.
Trial: NCT05292677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of Normal Saline
Trial: NCT05539053
Drug: N Acetylcysteine A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel + N-Acetylcysteine orally short course
Trial: NCT05539053
Drug: N Acetylcysteine B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel +N Acetylcysteine orally long course
Trial: NCT06449625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide placebo
Trial: NCT04124367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml once daily 0.9% saline
Trial: NCT00411515
Drug: Mycophenolate Mofetil 2x 1g
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05569577
Drug: Additional hCG injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An additional hCG injection of 2000-5000IU would be given 48 hours following routine hCG trigger and ovulation for LPS on the basis of supplementation of estrogen and dydrogesterone.
Trial: NCT05475873
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.
Trial: NCT06217406
Drug: Saline bags
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized in the control arm will receive placebo, eg. saline bags (same volume as acyclovir bags) every 8 hours during 14 days (treatment will be stopped in case of ICU discharge).
Trial: NCT06510426
Drug: Rebif 44 MCG Per 0.5 ML Prefilled Syringe
RxNorm normalized name: Rebif 44 MCG per 0.5 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebif 44mcg per 0.5ml administered subcutaneously
Trial: NCT06046560
Drug: SGLT2 inhibitor, GLP-1 RA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention.
Trial: NCT05136391
Drug: XTR003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 8.0-10 mCi of XTR003 will be injected on the first day of the study (Day 1). Serial whole-body PET imaging will be acquired after dose injection.
Trial: NCT06535126
Drug: CanProFem-AK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form - vaginal suppositories (100 mg). Dosage regimen - single intravaginal administration of suppository. Vaginal suppositories are inserted as deeply as possible while the participant is lying down; the participant must remain in a horizontal position for 45 minutes after the administration. The total duration of volunteer participation in the study is one day. Medical observation (including gynaecological monitoring with vaginal bacterial swab test) of the subject condition after the drug administration will be carried out after 3, 6, 9, 12 and 24 hours. Repeated laboratory blood and urine tests will be performed after 24 hours. Participants of the study will be closely monitored for 24 hours after the initial administration of the drug to detect any immediate adverse events. If the subject experiences an immediate adverse event, appropriate treatment will be provided.
Trial: NCT05128617
Drug: Epirubicin-cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cycle of Epirubicin-cyclophosphamide
Trial: NCT04723537
Drug: Part A and B: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 2 capsules, each capsule a matching placebo
Trial: NCT05027269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by intravenous (IV) infusion.
Trial: NCT05965570
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets.
Trial: NCT01231191
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg administered over 15 minutes intravenously as soon as feasible intraoperatively.
Trial: NCT01231191
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administered over 15 minutes intravenously as soon as feasible intraoperatively.
Trial: NCT05959499
Drug: BR6002A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT06256419
Drug: responders group and nonresponders group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For all the patients with type 2 diabetes who were initially enrolled in the study, blood samples were obtained for genotyping before the administration of GLP-1 receptor agonists. Patients were re-screened according to whether they had used GLP-1 RA continuously for more than 6 months and had completed the specified follow-up tasks.~Patients were divided according to the type of T2DM susceptibility genes. Or all were divided into responses group and nonresponses group according to whether they had glycemic response (△HbA1c↓ ≥1.0%) and weight response (△weight↓ ≥3.0%) after taking GLP-1 receptor agonist for 6 months.~According to the above grouping, the variables that can predict the efficacy of the drug were identified, and the weight of the influence of these variables on the efficacy was evaluated.
Trial: NCT04897763
Drug: 89Zr-TLX250 PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretherapeutic 89Zr-TLX250 PET/CT
Trial: NCT05959499
Drug: BR6002B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT05959499
Drug: BR6002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule administered alone
Trial: NCT04837040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, tablets, once daily by mouth
Trial: NCT05015894
Drug: NNC0480-0389
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 18 mg NNC0480 0389 administered subcutaneously (under the skin).~Total duration of study participation for each participant is 38 to 66 days
Trial: NCT00960817
Drug: Statin, aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05513976
Drug: SHR4640 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4640 tablet 5mg
Trial: NCT05513976
Drug: SHR4640 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4640 tablet 10mg
Trial: NCT05513976
Drug: SHR4640 placebo tablet
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4640 placebo tablet 5 or 10mg
Trial: NCT06498037
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of subcutaneously administered fentanyl loading boluses
Trial: NCT04885049
Drug: DiaResQ Children's Powder for Suspension
RxNorm normalized name: DiaResQ Children's Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral immunoglobulins
Trial: NCT05926206
Drug: Modified FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin- 85 mg/m2, IV over 120 minutes, day 1 Leucovorin/folinic acid- 400 mg/m2, IV over 90 minutes, day 1 Irinotecan- 150 mg/m2, IV over 90 minutes, day 1 5FU- 2400 mg/m2, IV over 42-48 hours after irinotecan, day 1